Acta Biomedica Scientifica (May 2012)

CLINICAL EFFECTS OF MESENCHYMAL STROMAL CELLS IN LYMPHOMA PATIENTS WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION

  • E. V. Batorov,
  • E. Ya. Shevela,
  • I. V. Kryuchkova,
  • D. S. Baranova,
  • V. V. Sergeevicheva,
  • S. A. Sizikova,
  • G. Yu. Ushakova,
  • A. V. Gilevich,
  • A. A. Ostanin,
  • E. R. Chernykh

Journal volume & issue
Vol. 0, no. 3(2)
pp. 33 – 37

Abstract

Read online

The clinical and laboratory effects of bone-marrow derived mesenchymal stromal cells (MSC) in patients with malignant lymphomas following autologous hematopoietic stem cell transplantation (auto-HSCT) have been investigated. Co-transplantation of MSC in average dose of 0,178 106/kg was conducted in 74 patients with auto-HSCT. The control group included 83 patients eligible for standard HSCT. We revealed the decreasing of the period of neutropenia and thrombocytopenia when hematopoietic stem cells were co-transplanted with low doses ex vivo expanded autologous MSC. Patients with MSC co-transplantation were differed by more effective early lymphocyte recovery. At the same time MSC co-transplantation did not increase the incidence of infectious complications and cases of renal and. hepatic toxicity. Patients with MSC co-transplantation did not differ from opposite group by 5-year overall survival, but were characterized by significantly better progression-free survival.

Keywords